Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice
NCT ID: NCT06018181
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2008 participants
OBSERVATIONAL
2023-09-28
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Although 35-53% of AIS patients achieve functional independence after receiving IVT, there are still a large number of patients who are disabled or even dead, and nearly 70% of patients have ineffective recanalization. Therefore, there is an urgent need for therapeutic drugs after IVT to further improve the prognosis and reduce the burden of AIS.
Shuxuetong injection is widely used in China in patients with AIS after IVT, but the situation in real clinical practice is unclear. Therefore, the study aims to evaluate the effectiveness and safety of Shuxuetong Injection in patients with AIS treated with intravenous alteplase and tenecteplase, and obtain high-quality clinical evidence.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5
NCT06196320
A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Stroke
NCT06621121
Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China
NCT06078995
Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)
NCT06010628
Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset
NCT07094763
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposure group
The exposure group was defined as patients receiving Shuxuetong injection and guideline-standardized treatment after intravenous alteplase or tenecteplase.
Mainly based on the following guidelines:(1)Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018; (2)Guidelines for secondary prevention of ischemic stroke and transient ischemic attack in China 2022.
Shuxuetong Injection
According to clinical real treatment records
Non-exposure group
The non-exposed group was defined as patients receiving guideline-standardized treatment after intravenous alteplase or tenecteplase.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Shuxuetong Injection
According to clinical real treatment records
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute ischemic stroke
* Receiving alteplase or tenecteplase treatment ≤ 4.5 hours of onset
* Signed informed consent by patient or legally authorized representatives
Exclusion Criteria
* Life expectancy is less than 90 days
* Other factors that the researchers think are not suitable for participating in the research
* Currently receiving any experimental treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dongzhimen Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ying Gao
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Royal Integrative Medicine Hospital
Beijing, Beijing Municipality, China
China Aerospace Science and Industry Corporation 731 Hospital
Beijing, Beijing Municipality, China
Chongqing Chinese Medicine Hospital
Chongqing, Chongqing Municipality, China
University-Town Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Nanning First People's Hospital
Nanning, Guangxi, China
Guizhou People's Hospital
Guiyang, Guizhou, China
Hebei CangZhou Hospital of Integrated Traditional Chinese and Western Medicine
Cangzhou, Hebei, China
Tangshan Central Hospital
Tangshan, Hebei, China
The First Affiliated Hospital Of Harbin Medical University
Harbin, Heilongjiang, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Hongqi Hospital Affiliated to Mudanjiang Medical University
Mudanjiang, Heilongjiang, China
Anyang Third People's Hospital
Anyang, Henan, China
Huaxian People's Hospital
Anyang, Henan, China
Neihuang People's Hospital
Anyang, Henan, China
Jiaozuo Second People's Hospital
Jiaozuo, Henan, China
Kaifeng People's Hospital
Kaifeng, Henan, China
Luohe Sixth People's Hospital
Luohe, Henan, China
Nanyang Nanshi Hospital
Nanyang, Henan, China
Baofeng Chinese Medicine Hospital
Pingdingshan, Henan, China
Baofeng People's Hospital
Pingdingshan, Henan, China
Pingdingshan First People's Hospital
Pingdingshan, Henan, China
Ye County People's Hospital
Pingdingshan, Henan, China
Shangqiu Municipal Hospital
Shangqiu, Henan, China
Changyuan Chinese Medicine Hospital
Xinxiang, Henan, China
The First Affiliated Hospital Of Xinxiang Medical University
Xinxiang, Henan, China
Xinxiang Central Hospital
Xinxiang, Henan, China
Xinxiang First People's Hospital
Xinxiang, Henan, China
Xi County Central Hospital
Xinyang, Henan, China
The First Affiliated Hospital of Henan University of Chinese Medicine
Zhengzhou, Henan, China
Runan People's Hospital
Zhumadian, Henan, China
Changsha First Hospital
Changsha, Hunan, China
The Affiliated Hospital of Hunan Academy of Chinese Medicine
Changsha, Hunan, China
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Hunan, China
Nanjing Chinese Medicine Hospital
Nanjing, Jiangsu, China
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Pengzhou Chinese Medicine Hospital
Pengzhou, Jiangsu, China
Yancheng First People's Hospital
Yancheng, Jiangsu, China
Gaoxin Hospital Of The First Affiliated Hospital Of Nanchang University
Nanchang, Jiangxi, China
Jiangxi People's Hospital
Nanchang, Jiangxi, China
Jilin Central General Hospital
Jilin, Jilin, China
Songyuan Jilin Oifield Hospital
Songyuan, Jilin, China
Anshan Central Hospital
Anshan, Liaoning, China
967 Hospital of The Joint Logistics Support Force of PLA
Dalian, Liaoning, China
Central Hospital Affiliated Dalian University of Technology
Dalian, Liaoning, China
Dalian University Affiliated Xinhua Hospital
Dalian, Liaoning, China
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
The Second Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
Jinzhou Central Hospital
Jinzhou, Liaoning, China
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Shenyang, Liaoning, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Tieling Central Hospital
Tieling, Liaoning, China
Binzhou Medical University Hospital/ The First School of Clinical Medicine of Binzhou Medical University
Binzhou, Shandong, China
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Jinan, Shandong, China
The Second Hospital of Shandong University
Jinan, Shandong, China
Liaocheng Third People's Hospital
Liaocheng, Shandong, China
Linyi Hospital of Traditional Chinese Medicine
Linyi, Shandong, China
Ningjin People's Hospital
Ningjin, Shandong, China
Qingdao Huangdao District Chinese Medicine Hospital
Qingdao, Shandong, China
Weihai Wendeng District People's Hospital
Weihai, Shandong, China
Zibo First Hospital
Zibo, Shandong, China
Zibo Hospital of Traditional Chinese Medicine
Zibo, Shandong, China
Shanghai Pingdingshan Hospital of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, China
Affiliated Hospital Of Changzhi Institute Of TCM
Changzhi, Shanxi, China
Gujiao Central Hospital
Taiyuan, Shanxi, China
Chengdu Integrated TCM & Western Medicine Hospital
Chengdu, Sichuan, China
Chengdu Seventh People's Hospital
Chengdu, Sichuan, China
Chengdu Shuangliu District Chinese Medicine Hospital
Chengdu, Sichuan, China
Chengdu Xinjin District Chinese Medicine Hospital
Chengdu, Sichuan, China
Jintang Second People's Hospital
Chengdu, Sichuan, China
Sichuan Tianfu People's Hospital
Chengdu, Sichuan, China
The Fourth People's Hospital of Sichuan Province
Chengdu, Sichuan, China
Xuyong Chinese Medicine Hospital
Luzhou, Sichuan, China
Qingshen People's Hospital
Meishan, Sichuan, China
Mianyang Third People's Hospital
Mianyang, Sichuan, China
Nanchong Central Hospital
Nanchong, Sichuan, China
Panzhihua Central Hospital
Panzhihua, Sichuan, China
Yibin Chinese Medicine Hospital
Yibin, Sichuan, China
Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022YFC3501104-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.